VC Biotech Funding Collapses Amid Crowded Market

American biotechs strapped for cash apparently have a rough road ahead. GlobalData reports that, compared to a year ago, venture financing deal value for U.S. biotechs dropped 46% in the first quarter. Causation is linked to a general market downturn in the sector as well as a plethora of geopolitical uncertainties...